NCT05218434View on ClinicalTrials.gov

A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

November 16, 2022

Study Completion Date

December 3, 2022

Conditions
Autoimmune Diseases
Interventions
DRUG

AX-158

Oral administrations of AX-158

Trial Locations (1)

Unknown

Simbec-Orion, Merthyr Tydfil

Sponsors

Collaborators (1)

Simbec-Orion Group
All Listed Sponsors
collaborator

Simbec-Orion Group

INDUSTRY

lead

Artax Biopharma Inc

INDUSTRY

NCT05218434 - A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses | Biotech Hunter | Biotech Hunter